Genchrome

Life Sciences | Innovation | Strategy

Your Partner To Drive Successful Drug Launches.

A leading biotech consulting company. We stand by biotech firms on their commercialization pathway,maximizing value from early clinical development to launch.

Nearly 50% of Biotech Launches Underperformed

Having Breakthrough Innovation Doesn’t Always Translate in a Successful Launch

New Biotech Launching Themselves Doesn't Always Know How to Implement Pharma Best Practices.

Preclinical

Phase 1

Phase 2

Phase 3

Launch

Consulting Approach

How we help?

At Genchrome, we understand that developing a new biotech Innovative Medicine can be challenging. It requires not only scientific expertise, but also business acumen. Genchrome with its ecosystem of pharma experts offers a range of services designed to support our biotech clients, from pre-clinical development to product launch.

Services

What We Offer?

We offer a wide range of services tailored to the life sciences field, addressing every stage from early development to commercial launch. Our solutions are designed to navigate the complexities of the industry, ensuring success and value for our partners.

Business Plan - Launch Planning

TPP* Seeking

Commercial Due Diligence

Benchmark Competitive Analysis

BD and M&A Support

Market Access Strategy

Pharma/Partnership

TPP*: Target Product Profile

Testimonials

What they say about us

“Genchrome’s expertise in  orphan drugs was greatly valued at Lupin Neurosciences. We particularly acknowledge both the operational support to the build of our commercial organization and the market access activities we had for our Orphan Drug, Namuscla!”

Home - Lupin Neurosciences

Thierry Volle, President at Lupin Atlantis Holdings SA

“We appreciated Genchrome’s strategic support Fab’entech’s phase 1/2 FabenCov’ asset. Great competitive analysis, positioning and pricing expertise which generated great value to Fabentech . Genchrome also helped set up an EU/KOL scientific advisory board and identify potential pharmaceutical partners. This has helped to convince our board and BPI  to add funds for the development of FabenCov.”

FAB'ENTECH - Lyonbiopôle

Sébastien Iva, CEO Fab’entech

 

“A deep understanding of each product market is essential. Genchrome helped us early on to analyze individual market mechanisms and identify relevant stakeholders as a basis to establish and challenge business case assumptions. It’s always been a pleasure to work with Genchrome’s senior industry experts.” | Scope: U.S/Canada/EU

About Polpharma Biologics.

Hannes Teissl , Chief Business Officer – Polpharma Biologics 

“It was my pleasure to work with Caroline [Founder & CEO at Genchrome] at Amgen UK & Ireland where she built the commercial organisation for the launch of our range of Biosimilars and in particular laid the ground for the successful launch of Amgevita. Her deep customer insight derived from building excellent relationships with senior customers in the NHS proved invaluable not only to the launch in the UK but also in the rest of Europe.”

John Kearney, former VP Western Europe, Middle-East and Africa – Amgen

“Caroline [Founder & CEO at Genchrome] has a proven track record of translating high-level strategies into practical plans, validating ideas and executing successful go-to-market initiatives. Backed by her experience in product development and global markets, Caroline has been a great partner to support the launch of our medicines at Amgen.”

Philippe Legenne, VP clinical development and external scientific engagement – Molecular Partners

All logos, trade marks and brands are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trade marks, logos and brands does not imply endorsement.

A Team Of Experts

A Deep Expertise in the Pharma & Biotech Sectors

Our team of experts at Genchrome has a broad expertise in the pharmaceutical and biotech sectors. We have professionals with years of experience in various areas of these industries, including drug development, regulatory affairs, clinical research, and commercialization.

Caroline BOULLIAT

CEO & Founder

Pharma D – Partner in Life Sciences. Biotech-Pharmaceutical executive global commercial leader. Multiple launch experience, Go-to Market Strategy, ability to drive growth and innovation.